Your browser is no longer supported. Please, upgrade your browser.
Settings
IRWD Ironwood Pharmaceuticals, Inc. daily Stock Chart
IRWD [NASD]
Ironwood Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.72 Insider Own0.40% Shs Outstand151.94M Perf Week-4.54%
Market Cap2.62B Forward P/E- EPS next Y-0.08 Insider Trans-24.45% Shs Float137.36M Perf Month-1.03%
Income-107.60M PEG- EPS next Q-0.22 Inst Own- Short Float15.61% Perf Quarter15.37%
Sales315.30M P/S8.32 EPS this Y-39.20% Inst Trans0.69% Short Ratio15.79 Perf Half Y10.57%
Book/sh-0.12 P/B- EPS next Y92.10% ROA-17.20% Target Price18.42 Perf Year-9.49%
Cash/sh1.28 P/C13.48 EPS next 5Y- ROE- 52W Range12.89 - 19.94 Perf YTD15.14%
Dividend- P/FCF- EPS past 5Y-2.80% ROI-19.40% 52W High-13.44% Beta1.08
Dividend %- Quick Ratio4.40 Sales past 5Y14.70% Gross Margin93.30% 52W Low33.90% ATR0.70
Employees730 Current Ratio4.40 Sales Q/Q32.60% Oper. Margin-23.30% RSI (14)46.67 Volatility2.50% 4.46%
OptionableYes Debt/Eq- EPS Q/Q19.60% Profit Margin-34.10% Rel Volume0.46 Prev Close17.57
ShortableYes LT Debt/Eq- EarningsMay 01 BMO Payout- Avg Volume1.36M Price17.26
Recom2.50 SMA20-4.97% SMA502.30% SMA20010.03% Volume617,977 Change-1.76%
May-09-18Downgrade Morgan Stanley Equal-Weight → Underweight
Jan-05-18Downgrade BofA/Merrill Buy → Underperform
Dec-06-17Downgrade Mizuho Buy → Neutral $16
Jul-21-17Downgrade JP Morgan Overweight → Neutral
May-03-17Initiated Wells Fargo Outperform
Apr-07-17Reiterated Mizuho Buy $21 → $22
Feb-22-17Reiterated Barclays Equal Weight $13 → $16
Nov-04-16Reiterated Mizuho Buy $19 → $20
Oct-24-16Reiterated Wedbush Neutral $10 → $13
Oct-10-16Reiterated Mizuho Buy $24 → $19
Sep-27-16Reiterated WallachBeth Hold $15 → $17
Jul-15-16Reiterated Mizuho Buy $16 → $24
May-10-16Reiterated Mizuho Buy $15 → $16
Apr-28-16Reiterated Wedbush Neutral $9 → $10
Mar-21-16Initiated Goldman Neutral
Feb-19-16Reiterated Wedbush Neutral $10 → $9
Apr-27-15Initiated BofA/Merrill Buy $19
Mar-04-15Initiated Barclays Equal Weight $18
Feb-13-15Reiterated WallachBeth Hold $15 → $17
Jul-09-14Initiated Furey Research Partners Buy $20
May-23-18 08:00AM  Ironwood Pharmaceuticals to Highlight Clinical Data for IW-3718 in Persistent Gastroesophageal Reflux Disease (GERD) at Digestive Disease Week® 2018 Business Wire
May-21-18 04:24PM  Wall Street Baffled Why Activist Sarissa Went Silent on Ironwood Bloomberg
May-14-18 07:30AM  Ironwood Pharmaceuticals Sends Letter to Shareholders Highlighting Director Nominees Business Wire
May-10-18 08:30AM  Today's Research Reports on Trending Tickers: Horizon Pharma and Ironwood Pharmaceuticals ACCESSWIRE
May-09-18 10:13AM  Morgan Stanley Turns Bearish On Ironwood Pharma, Lowers Linzess Sales Estimate Benzinga
08:30AM  Ironwood Pharmaceuticals Files Investor Presentation Highlighting Actions Taken Designed to Unlock Shareholder Value Business Wire
May-07-18 07:30AM  Detailed Research: Economic Perspectives on CASI Pharmaceuticals, Energy Transfer Partners, Cypress Semiconductor, Xcel Energy, Ironwood Pharmaceuticals, and KalVista Pharmaceuticals What Drives Growth in Today's Competitive Landscape GlobeNewswire
May-03-18 04:05PM  Ironwood and Allergan Announce Settlement with Aurobindo Pharma Resolving LINZESS® (linaclotide) Patent Litigation Business Wire
07:50AM  Blog Exposure - Ironwood to Separate Its Soluble Guanylate Cyclase Business from Commercial and Gastrointestinal Business ACCESSWIRE
May-02-18 01:27PM  Edited Transcript of IRWD earnings conference call or presentation 1-May-18 12:30pm GMT Thomson Reuters StreetEvents
11:00AM  Ironwood (IRWD) Incurs Loss in Q1, Announces Restructuring Zacks
10:15AM  Ironwood slams Denner's bid for board seat as proxy fight looms American City Business Journals
08:00AM  Ironwood Pharmaceuticals Files Definitive Proxy Materials and Mails Letter to Shareholders Business Wire
May-01-18 09:45PM  [$$] Ironwood Will Separate From Its Rare-Disease Drug Unit After Pressure The Wall Street Journal
04:01PM  Allergan and Ironwood Launch Interactive Digital Destination During Irritable Bowel Syndrome (IBS) Awareness Month Designed to Encourage Sufferers to Get Educated and Take Action PR Newswire
03:18PM  Ironwood Pharma may satisfy activist Denner with split-up plan, but he still wants a board seat CNBC
10:08AM  Ironwood: 1Q Earnings Snapshot Associated Press
08:30AM  Cambridges Ironwood Pharmaceuticals to split into two businesses American City Business Journals
07:58AM  Ironwood Pharmaceuticals Announces Intent to Separate Soluble Guanylate Cyclase (sGC) Business from Commercial and Gastrointestinal Business Business Wire
07:55AM  Ironwood Pharmaceuticals Provides First Quarter 2018 Investor Update Business Wire
Apr-17-18 04:01PM  Ironwood Pharmaceuticals to Host First Quarter 2018 Investor Update Call Business Wire
Apr-09-18 04:50PM  Biotech activist Alex Denners next target: Ironwood Pharma CNBC +10.52%
08:00AM  Ironwood Pharmaceuticals Announces Director Nomination from Sarissa Capital Business Wire
Mar-06-18 12:59PM  Whats The Market Sentiment Around Loss-Making Ironwood Pharmaceuticals Inc (NASDAQ:IRWD)? Simply Wall St.
Mar-05-18 04:01PM  Ironwood Pharmaceuticals to Present at Upcoming March Investor Conferences Business Wire
07:40AM  Analysis: Positioning to Benefit within Ironwood Pharmaceuticals, Altaba, The AES, PACCAR, NVR, and WPX Energy Research Highlights Growth, Revenue, and Consolidated Results GlobeNewswire
Feb-26-18 07:20AM  Blog Exposure - FDA Accepted Mallinckrodts New Drug Application for Stannsoporfin for Severe Hyperbilirubinemia ACCESSWIRE
Feb-16-18 08:44AM  Ironwood (IRWD) Beats Estimates in Q4 Earnings, Stock Up Zacks
08:10AM  Todays Research Reports on Stocks to Watch: Ironwood Pharmaceuticals and Teva Pharmaceutical ACCESSWIRE
02:45AM  Edited Transcript of IRWD earnings conference call or presentation 15-Feb-18 1:30pm GMT Thomson Reuters StreetEvents
Feb-15-18 08:43AM  Ironwood beats Street 4Q forecasts Associated Press +6.97%
08:01AM  Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2017 Investor Update Business Wire
Feb-14-18 08:59AM  Ironwood Pharmaceuticals Incs (NASDAQ:IRWD) Earnings Dropped -73.31%, Did Its Industry Show Weakness Too? Simply Wall St.
Feb-01-18 04:01PM  Ironwood Pharmaceuticals to Host Fourth Quarter and Full-Year 2017 Investor Update Call Business Wire -5.60%
Jan-25-18 08:20AM  Todays Research Reports on Trending Tickers: Aerie Pharmaceuticals and Ironwood Pharmaceuticals ACCESSWIRE
Jan-16-18 08:30AM  Ironwood and Allergan Announce Settlement with Sun Pharma Resolving LINZESS® (linaclotide) Patent Litigation Business Wire
08:03AM  See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. Markit
Jan-12-18 08:10AM  Todays Research Reports on Stocks to Watch: Agios Pharmaceuticals, Inc. and Ironwood Pharmaceuticals, Inc. ACCESSWIRE
Jan-11-18 08:02AM  See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. Markit +9.03%
Jan-10-18 08:02AM  See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. Markit
Jan-04-18 02:33PM  Here's Why Ironwood Pharmaceuticals, Inc. Stock Slipped 13.2% in December Motley Fool
Jan-02-18 04:01PM  Ironwood Pharmaceuticals to Present at J.P. Morgan Healthcare Conference Business Wire
08:03AM  See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. Markit
Dec-26-17 11:41AM  ETFs with exposure to Ironwood Pharmaceuticals, Inc. : December 26, 2017 Capital Cube
Dec-22-17 09:25AM  Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q3, 2017 By the Numbers : December 22, 2017 Capital Cube
07:32AM  Sucampo Pharmaceuticals Amitiza: Its Competitive Landscape Market Realist
Dec-21-17 08:00AM  Ironwood Pharmaceuticals Initiates Phase II Clinical Trial of sGC Stimulator IW-1701 in Patients with Sickle Cell Disease Business Wire
Dec-18-17 08:04AM  Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US : December 18, 2017 Capital Cube
Dec-08-17 02:03PM  Ironwood Pharmaceuticals, Inc. Value Analysis (NASDAQ:IRWD) : December 8, 2017 Capital Cube
Dec-07-17 07:56AM  Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IRWD-US : December 7, 2017 Capital Cube
Dec-05-17 09:05AM  Ironwood Succeeds in Diabetic Hypertension Phase II Study Zacks
Dec-04-17 09:29AM  Ironwood Jumps on Phase 2a Data; Ultragenyx Climbs -- Biotech Movers TheStreet.com -6.18%
08:16AM  Ironwood Pharma stock jumps 3.5% on positive trials of treatment for type 2 diabetes MarketWatch
08:05AM  Ironwood Reports Top-line Phase IIa Data for IW-1973 Demonstrating Positive Cardiovascular, Metabolic and Endothelial Effects Business Wire
Nov-28-17 08:00AM  Today's Research Reports on Trending Tickers: UnitedHealth Group Inc. and Ironwood Pharmaceuticals, Inc. ACCESSWIRE
08:00AM  Ironwood Pharmaceuticals Strengthens Executive Leadership Team Business Wire
Nov-27-17 01:31PM  Could The Street Be Underappreciating The Ironwood Pharma Pipeline? Benzinga
08:03AM  See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. Markit
Nov-21-17 07:34AM  Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US : November 21, 2017 Capital Cube
Nov-15-17 08:08AM  See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. Markit
Nov-10-17 08:06AM  See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. Markit
Nov-08-17 08:30AM  See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. Markit
Nov-07-17 10:21AM  Edited Transcript of IRWD earnings conference call or presentation 2-Nov-17 12:30pm GMT Thomson Reuters StreetEvents
08:09AM  See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. Markit
Nov-06-17 08:20AM  Market Trends Toward New Normal in Public Service Enterprise Group, Rigel Pharma, National Oilwell Varco, Ironwood Pharma, Express Scripts, and Synergy Pharma Emerging Consolidated Expectations, Analyst Ratings GlobeNewswire
07:17AM  Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US : November 6, 2017 Capital Cube
Nov-03-17 01:39PM  Ironwood (IRWD) Beats Estimates in Q3 Earnings, Stock Up Zacks
08:01AM  See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. Markit
Nov-02-17 08:27AM  Ironwood reports 3Q loss Associated Press
08:01AM  Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update Business Wire
Nov-01-17 04:01PM  Ironwood Pharmaceuticals to Present at Credit Suisse 26th Annual Healthcare Conference Business Wire
Oct-30-17 08:00AM  Ironwood Highlights Breadth of Gout Research to be Presented at the 2017 ACR/ARHP Annual Meeting Business Wire
Oct-23-17 08:02AM  See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. Markit
Oct-19-17 04:01PM  Ironwood Pharmaceuticals to Host Third Quarter 2017 Investor Update Call Business Wire
Oct-17-17 08:04AM  See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. Markit
Oct-16-17 10:07AM  Ironwood Pharmaceuticals, Inc. Value Analysis (NASDAQ:IRWD) : October 16, 2017 Capital Cube
09:54AM  ETFs with exposure to Ironwood Pharmaceuticals, Inc. : October 16, 2017 Capital Cube
08:00AM  Ironwood Pharmaceuticals Presenting Linaclotide Data at the World Congress of Gastroenterology at ACG 2017 Business Wire
Oct-13-17 08:36AM  Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bearish Manner : IRWD-US : October 13, 2017 Capital Cube
Oct-09-17 09:30AM  Dont Miss Out On These Tantalizing Sohn Conference Stock Pitches Insider Monkey
Oct-03-17 11:20AM  ETFs with exposure to Ironwood Pharmaceuticals, Inc. : October 3, 2017 Capital Cube
Oct-02-17 08:03AM  See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. Markit
Sep-28-17 08:03AM  See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. Markit
Sep-27-17 08:02AM  See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. Markit
Sep-26-17 08:12AM  Ironwood Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : IRWD-US : September 26, 2017 Capital Cube
Sep-13-17 06:42PM  ETFs with exposure to Ironwood Pharmaceuticals, Inc. : September 13, 2017 Capital Cube
Sep-11-17 02:43PM  Ironwood Pharmaceuticals, Inc. :IRWD-US: Earnings Analysis: Q2, 2017 By the Numbers : September 11, 2017 Capital Cube
Sep-06-17 08:00AM  Ironwood Pharmaceuticals Announces Leadership Change Business Wire
Sep-04-17 07:22AM  Why Is Ironwood (IRWD) Down 4.1% Since the Last Earnings Report? Zacks
Aug-31-17 04:01PM  Ironwood Pharmaceuticals to Present at Upcoming September Investor Conferences Business Wire
Aug-23-17 08:10AM  Today's Research Reports on Stocks to Watch: Medtronic and Ironwood Pharmaceuticals ACCESSWIRE
08:02AM  See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. Markit
07:56AM  Biotech Stock Roundup: EU Label Expansion for Alexion, BIIB Facing Drug Price Probe Zacks
Aug-22-17 10:46AM  Ironwood Pharma's Combination Gout Drug Gets FDA Approval Zacks
Aug-21-17 12:50PM  Ironwood gets FDA approval for new drug for gout American City Business Journals
11:38AM  Ironwood Pharma Muted Despite FDA Approval 24/7 Wall St.
09:33AM  Ironwood Shares Jump on FDA Approval for Hyperuricemia Drug - Biotech Movers TheStreet.com
09:18AM  FDA approves Ironwood Pharma's gout drug Reuters
08:00AM  Ironwood Pharmaceuticals Announces FDA Approval of DUZALLO® (lesinurad and allopurinol) for the Treatment of Hyperuricemia in Patients with Uncontrolled Gout Business Wire
Aug-16-17 08:03AM  See what the IHS Markit Score report has to say about Ironwood Pharmaceuticals Inc. Markit
Ironwood Pharmaceuticals, Inc., a commercial biotechnology company, engages in the research, development, and commercialization of human therapeutic products. The company markets linaclotide, a guanylate cyclase type-C agonist for the treatment of adults suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC) under the LINZESS name in the United States and CONSTELLA name in the European Union; and lesinurad for the treatment of hyperuricemia associated with uncontrolled gout in adults under the ZURAMPIC and DUZALLO names. Ironwood Pharmaceuticals, Inc. has collaboration agreements with Allergan plc and AstraZeneca AB to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other gastrointestinal (GI) conditions in North America, China, Hong Kong, and Macau; and a license agreement with Astellas Pharma Inc. to develop and commercialize linaclotide for the treatment of IBS-C, CIC, and other GI conditions in Japan. The company was formerly known as Microbia, Inc. and changed its name to Ironwood Pharmaceuticals, Inc. in April 2008. Ironwood Pharmaceuticals, Inc. was founded in 1998 and is headquartered in Cambridge, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
OLANOFF LAWRENCE SDirectorMar 05Sale14.052,00028,10029,330Mar 06 07:17 PM
McHugh JulieDirectorMar 05Sale14.061,50021,09077,908Mar 06 07:15 PM
Currie Mark GChief Scientific OfficerFeb 21Sale14.661,63423,95418,124Feb 22 06:06 PM
MCCOURT Thomas AChief Commercial OfficerFeb 21Sale14.663,34349,00852,638Feb 22 06:05 PM
Gilbert Halley EChief Legal OfficerFeb 21Sale14.667,741113,48394,204Feb 22 06:04 PM
Consylman GinaChief Financial OfficerFeb 21Sale14.663,59452,68855,907Feb 22 06:02 PM
Currie Mark GChief Scientific OfficerJan 24Option Exercise3.7660,000225,600835,000Jan 26 04:09 PM
Currie Mark GChief Scientific OfficerJan 24Sale15.4560,000927,000775,000Jan 26 04:09 PM
Hecht Peter MChief Executive OfficerDec 07Option Exercise3.7657,405215,8434,754,322Dec 08 05:00 PM
Hecht Peter MChief Executive OfficerDec 07Sale15.0057,405861,0754,696,917Dec 08 05:00 PM
Hecht Peter MChief Executive OfficerDec 06Option Exercise3.7682,595310,5574,752,917Dec 08 05:00 PM
Hecht Peter MChief Executive OfficerDec 06Sale15.2456,000853,4404,696,917Dec 08 05:00 PM
OLANOFF LAWRENCE SDirectorDec 04Sale16.462,00032,92131,330Dec 06 04:14 PM
McHugh JulieDirectorDec 04Sale16.451,50024,67579,408Dec 06 04:12 PM
Consylman GinaInterim CFO and CAONov 10Sale15.2086413,13352,001Nov 14 04:10 PM
OLANOFF LAWRENCE SDirectorSep 05Sale16.152,00032,30033,330Sep 07 04:40 PM
McHugh JulieDirectorSep 05Sale16.161,50024,24080,908Sep 07 04:38 PM
Consylman GinaChief Accounting OfficerAug 18Sale14.342072,96852,865Aug 22 04:07 PM
Gilbert Halley EChief Legal OfficerJun 22Option Exercise3.7635,000131,60035,000Jun 26 04:22 PM
Gilbert Halley EChief Legal OfficerJun 22Sale19.7535,000691,2500Jun 26 04:22 PM
OLANOFF LAWRENCE SDirectorJun 08Sale17.783,20056,89635,330Jun 12 04:27 PM